Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | TP53 | P04637 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6684875 | 0.92 | MAPT (0.49) | MAPTTP53LMNAPOLBCNR1 | |
| SCHEMBL6679778 | 0.91 | MAPT (0.47) | MAPTTP53LMNAPOLBCNR1 | |
| SCHEMBL6678534 | 0.90 | MAPT (0.48) | MAPTTP53LMNAPOLBCNR1 | |
| SCHEMBL6683273 | 0.90 | MAPT (0.49) | MAPTTP53LMNAPOLBCNR1 | |
| SCHEMBL6680500 | 0.90 | MAPT (0.47) | MAPTTP53LMNAPOLBCNR1 | |
| SCHEMBL6678320 | 0.88 | MAPT (0.55) | MAPTTP53LMNAPOLBRAB9A | |
| SCHEMBL6681366 | 0.87 | MAPT (0.56) | MAPTTP53LMNAPOLBCNR1 | |
| SCHEMBL6680173 | 0.84 | ALDH1A1 (0.53) | MAPTTP53LMNAPOLBTHRB | |
| SCHEMBL6664864 | 0.83 | MAPT (0.47) | MAPTTP53LMNAPOLBCNR1 | |
| SCHEMBL6682598 | 0.82 | MAPT (0.51) | MAPTTP53LMNAPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014388-A1 | 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP26, MMP9 | MAPT 2365/4885TP53 4473/4885LMNA 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.